In The Translational Biomarkers in Aging and Dementia (TRIAD) study, plasma GFAP levels were precise in capturing the brain pathology so that it was possible to discern between preclinical AD, clinical AD, and cognitively unimpaired Aβ-negative individuals [159]. This evidence concerns the gene GFAP and dementia.